SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4915-4919

  Huber, Andrew D ^a   Michailidis, Eleftherios ^a,b   Schultz, Megan L ^c   Ong, Yee T ^a,b   Bloch, Nicolin ^c   Puray Chavez, Maritza N ^a,b   Leslie, Maxwell D ^a,b   Ji, Juan ^a,b   Lucas, Anthony D ^a,b   Kirby, Karen A ^a,b   Landau, Nathaniel R ^c   Sarafianos, Stefan G ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; DIDEOXYNUCLEOTIDE; LAMIVUDINE; LUCIFERASE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAMHD1 PROTEIN, HUMAN; SMALL INTERFERING RNA; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONOCYTE; REPORTER GENE; VIROLOGY; VIRUS REPLICATION;

ADENINE; CELL LINE; DIDEOXYNUCLEOTIDES; GENE EXPRESSION; GENES, REPORTER; HIV REVERSE TRANSCRIPTASE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LAMIVUDINE; LUCIFERASES; MONOCYTES; MONOMERIC GTP-BINDING PROTEINS; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, SMALL INTERFERING; STAVUDINE; TENOFOVIR; VIRUS REPLICATION; ZIDOVUDINE;

EID: 84905380670     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02745-14     Document Type: Article

References (63)

1. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545-51553. http://dx.doi.org/10.1074/jbc. M408573200.
2. Kennedy EM, Gavegnano C, Nguyen L, Slater R, Lucas A, Fromentin E, Schinazi RF, Kim B. 2010. Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J. Biol. Chem. 285:39380-39391. http://dx.doi.org/10.1074/jbc.M110.178582.
3. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. 2012. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13:223-228. http://dx.doi.org/10.1038/ni.2236.
4. + T cells. Nat. Med. 18:1682-1687. http://dx.doi.org/10.1038/nm.2964.
5. + T-cells. Retrovirolog. 9:87. http://dx.doi.org/10.1186/1742-4690-9-87.
6. + T-lymphocytes cannot be upregulated by interferons. Retrovirolog. 9:105. http://dx.doi.org/10.1186/1742-4690-9-105.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Natur. 373:123-126. http://dx.doi.org/10.1038/373123a0.
8. Coleman CM, Wu L. 2009. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirolog. 6:51. http://dx.doi.org/10. 1186/1742-4690-6-51.
9. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. 2010. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Natur. 467:214-217. http://dx.doi.org/10.1038/nature09337.
10. Bergamaschi A, Pancino G. 2010. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirolog. 7:31. http://dx.doi.org/10.1186/1742- 4690-7-31.
11. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Natur. 474:654-657. http://dx.doi.org/10.1038/nature10117.
12. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Natur. 474:658-661. http://dx.doi.org/10.1038/nature10195.
13. + cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7:e1002425. http://dx.doi.org/10.1371/journal.ppat.1002425.
14. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA, Webb M. 2011. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Natur. 480:379-382. http://dx.doi.org/10.1038/nature10623.
15. Powell RD, Holland PJ, Hollis T, Perrino FW. 2011. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTPregulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 286:43596-43600. http://dx.doi.org/10.1074/jbc.C111.317628.
16. White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen L, Kim B, Brojatsch J, Diaz-Griffero F. 2013. Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virolog. 436:81-90. http://dx.doi.org/10.1016/j.virol.2012.10.029.
17. Kim B, Nguyen LA, Daddacha W, Hollenbaugh JA. 2012. Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J. Biol. Chem. 287:21570-21574. http://dx.doi.org/10.1074/jbc.C112.374843.
18. Beloglazova N, Flick R, Tchigvintsev A, Brown G, Popovic A, Nocek B, Yakunin AF. 2013. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J. Biol. Chem. 288:8101-8110. http://dx.doi.org/10.1074/jbc.M112.431148.
19. Amie SM, Daly MB, Noble E, Schinazi RF, Bambara RA, Kim B. 2013. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J. Biol. Chem. 288:20683-20691. http://dx.doi.org/ 10.1074/jbc.M113.472159.
20. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA, International AIDS Society-USA Panel. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAM. 296:827-843. http://dx.doi.org/10.1001/jama.296.7.827.
21. Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ. 2006. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res. 71:322-334. http://dx.doi.org/10.1016/j.antiviral.2006. 03.012.
22. Parniak MA, Sluis-Cremer N. 2000. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol. 49:67-109. http://dx.doi.org/10.1016/S1054- 3589(00)49024-1.
23. De Clercq E. 2007. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Verh. K. Acad. Geneeskd. Belg. 69:81-104. http://dx.doi.org/10.1016/j.ijantimicag.2008.10.010.
24. Deval J. 2009. Antimicrobial strategies: inhibition of viral polymerases by 3=-hydroxyl nucleosides. Drug. 69:151-166. http://dx.doi.org/10.2165/ 00003495-200969020-00002.
25. Ilina T, Parniak MA. 2008. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol. 56:121-167. http://dx.doi.org/10.1016/S1054-3589(07)56005-9.
26. Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG. 2010. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruse. 2:606-638. http://dx.doi.org/10.3390/v2020606.
27. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713. http://dx.doi.org/10.1016/j.jmb.2008.10.071.
28. Menendez-Arias L. 2002. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23:381-388. http://dx.doi.org/10.1016/S0165-6147(02)02054-0.
29. Menendez-Arias L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134:124-146. http://dx.doi.org/10.1016/j.virusres.2007.12.015.
30. Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, Matsuoka M. 2008. 2=-Deoxy-4=-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell Biol. 40:2410-2420. http://dx.doi.org/10.1016/j.biocel.2008.04.007.
31. Michailidis E, Marchand B, Kodama EN, Singh K, Matsuoka M, Kirby KA, Ryan EM, Sawani AM, Nagy E, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2009. Mechanism of inhibition of HIV-1 reverse transcriptase by 4=-ethynyl-2-fluoro-2= -deoxyadenosine triphosphate, a translocationdefective reverse transcriptase inhibitor. J. Biol. Chem. 284:35681-35691. http://dx.doi.org/10.1074/jbc.M109. 036616.
32. Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG. 2013. Hypersusceptibility mechanism of tenofovir-resistant HIV to EFdA. Retrovirolog. 10:65. http://dx.doi.org/10.1186/1742-4690-10-65.
33. Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, Sarafianos SG. 2013. Evaluation of combinations of 4=-ethynyl-2-fluoro-2=-deoxyadenosine with clinically used antiretroviral drugs. Antimicrob. Agents Chemother. 57:4554-4558. http://dx.doi.org/10.1128/AAC.00283-13.
34. Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG. 2012. Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant. Cell. Mol. Biol. (Noisy-le-grand. 58:187-195.
35. Kirby KA, Singh K, Michailidis E, Marchand B, Kodama EN, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2011. The sugar ring conformation of 4=-ethynyl-2-fluoro-2=-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. Cell. Mol. Biol. (Noisy-le-grand. 57:40-46.
36. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA. 2012. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4=-ethynyl-2-fluoro-2=-deoxyadenosine in vitro and in vivo. Antimicrob. Agents Chemother. 56:4707-4712. http://dx.doi.org/10.1128/AAC.00723-12.
37. Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG. 2013. Effects of substitutions at the 4= and 2 positions on the bioactivity of 4=-ethynyl-2-fluoro-2=-deoxyadenosine. Antimicrob. Agents Chemother. 57:6254-6264. http://dx.doi.org/10.1128/AAC.01703-13.
38. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, Hao Z, Gerrard TL, Wilson YA, Johns DG, Broder S. 1988. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2=, 3=-dideoxynucleosides. J. Exp. Med. 168:1111-1125. http://dx.doi.org/10.1084/ jem.168.3.1111.
39. Stein DS, Moore KH. 2001. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherap. 21:11-34. http://dx.doi.org/10.1592/phco.21.1.11.34439.
40. Ray AS. 2005. Intracellular interactions between nucleos (t) ide inhibitors of HIV reverse transcriptase. AIDS Rev. 7:113-125.
41. Welbourn S, Miyagi E, White TE, Diaz-Griffero F, Strebel K. 2012. Identification and characterization of naturally occurring splice variants of SAMHD1. Retrovirolog. 9:86. http://dx.doi.org/10.1186/1742-4690-9-86.
42. Gramberg T, Kahle T, Bloch N, Wittmann S, Mullers E, Daddacha W, Hofmann H, Kim B, Lindemann D, Landau NR. 2013. Restriction of diverse retroviruses by SAMHD1. Retrovirolog. 10:26. http://dx.doi.org/10.1186/1742-4690-10-26.
43. Meyer P, Schneider B, Sarfati S, Deville-Bonne D, Guerreiro C, Boretto J, Janin J, Veron M, Canard B. 2000. Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase. EMBO J. 19:3520-3529. http://dx.doi.org/10.1093/emboj/19.14.3520.
44. Anderson PL, Kakuda TN, Lichtenstein KA. 2004. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743-753. http://dx.doi.org/10.1086/381678.
45. Samuels DC. 2006. Mitochondrial AZT metabolism. IUBMB Lif. 58:403-408. http://dx.doi.org/10.1080/15216540600791571.
46. Johnson MA, Fridland A. 1989. Phosphorylation of 2=, 3=-dideoxyinosine by cytosolic 5=-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36:291-295.
47. Bradshaw PC, Samuels DC. 2005. A computational model of mitochondrial deoxynucleotide metabolism and DNA replication. Am. J. Physiol. Cell Physiol. 288:C989-C1002. http://dx.doi.org/10.1152/ajpcell.00530.2004.
48. Eriksson S, Munch-Petersen B, Johansson K, Eklund H. 2002. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 59:1327-1346. http://dx.doi.org/10.1007/s00018-002-8511-x.
49. Tornevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S. 1995. Cytotoxicity of 3=-azido-3=-deoxythymidine correlates with 3=-azidothymidine-5=- monophosphate (AZTMP) levels, whereas antihuman immunodeficiency virus (HIV) activity correlates with 3=-azidothymidine-5=-triphosphate (AZTTP) levels in cultured CEM Tlymphoblastoid cells. Biochem. Pharmacol. 49:829-837. http://dx.doi.org/10.1016/0006-2952(94)00453-S.
50. Qian M, Bui T, Ho RJ, Unadkat JD. 1994. Metabolism of 3=-azido-3=-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem. Pharmacol. 48:383-389. http://dx.doi.org/10.1016/0091-3057(94) 90542-8, http://dx.doi.org/10.1016/0006-2952 (94)90111-2.
51. Lavie A, Schlichting I, Vetter IR, Konrad M, Reinstein J, Goody RS. 1997. The bottleneck in AZT activation. Nat. Med. 3:922-924. http://dx.doi.org/10. 1038/nm0897-922.
52. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. 1994. Divergent antihuman immunodeficiency virus activity and anabolic phosphorylation of 2=, 3=-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
53. Furman PA, Fyfe JA, St. Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DW. 1986. Phosphorylation of 3=-azido-3=-deoxythymidine and selective interaction of the 5=-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 83:8333-8337. http://dx.doi.org/10.1073/pnas.83.21.8333.
54. Balzarini J, Herdewijn P, De Clercq E. 1989. Differential patterns of intracellular metabolism of 2=, 3=-didehydro-2=, 3=-dideoxythymidine and 3=-azido-2=, 3=-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264:6127-6133.
55. Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF. 2007. Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine. Antimicrob. Agents Chemother. 51:2130-2135. http://dx.doi.org/10. 1128/AAC.01543-06.
56. Schneider B, Xu YW, Sellam O, Sarfati R, Janin J, Veron M, Deville-Bonne D. 1998. Pre-steady state of reaction of nucleoside diphosphate kinase with anti-HIV nucleotides. J. Biol. Chem. 273:11491-11497. http://dx.doi.org/10.1074/ jbc.273.19.11491.
57. Bourdais J, Biondi R, Sarfati S, Guerreiro C, Lascu I, Janin J, Veron M. 1996. Cellular phosphorylation of anti-HIV nucleosides: role of nucleoside diphosphate kinase. J. Biol. Chem. 271:7887-7890.
58. Schneider B, Biondi R, Sarfati R, Agou F, Guerreiro C, Deville-Bonne D, Veron M. 2000. The mechanism of phosphorylation of anti-HIV D4T by nucleoside diphosphate kinase. Mol. Pharmacol. 57:948-953.
59. Ayinde D, Maudet C, Transy C, Margottin-Goguet F. 2010. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirolog. 7:35. http://dx.doi.org/10.1186/1742-4690-7-35.
60. Berger G, Durand S, Goujon C, Nguyen XN, Cordeil S, Darlix JL, Cimarelli A. 2011. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat. Protoc. 6:806-816. http://dx.doi.org/10.1038/nprot.2011.327.
61. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. 2006. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIVMAC. Gene Ther. 13:991-994. http://dx.doi.org/10.1038/sj.gt.3302753.
62. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. 2007. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirolog. 4:2. http://dx.doi.org/10.1186/1742-4690-4-2.
63. Laguette N, Rahm N, Sobhian B, Chable-Bessia C, Munch J, Snoeck J, Sauter D, Switzer WM, Heneine W, Kirchhoff F, Delsuc F, Telenti A, Benkirane M. 2012. Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microb. 11:205-217. http://dx.doi.org/10.1016/j.chom.2012.01.007.